Abstract:Background: The aim of this study was to assess the predictive value of tumor expression of ataxia telangiectasia-mutated (ATM), checkpoints kinase 2 (CHK2) and breast cancer susceptibility gene1 (BRCA1) on clinical outcome in patients with advanced non-small cell lung cancer (NSCLC) receiving platinum-based chemotherapy. Methods: Immunohistochemistry was used to analyze the expression of ATM, CHK2 and BRCA1 isolated from paraffin-embedded tumor biopsies of 101 NSCLC patients. All NSCLC patients received first-line platinum chemotherapy. Results: There was a significant relationship observed between ATM and CHK2. However, a correction was observed between the expression of CHK2 and patients’ age. Patients below 60 years had a lower CHK2 expression than those above 60 years. Patients with low CHK2 or BRCA1 expression had a longer OS as compared to patients with high CHK2 or BRCA1 expression. Median OS was 34 months in the squamous NSCLC and median OS was 14 months in the mixed NSCLC. Conclusions: Our results suggest that CHK2 and BRCA1 expressions are associated with the prognosis in NSCLC patients treated with platinum-based chemotherapy. Clinical outcomes could be improved by additional targeting CHK2 to refine BRCA1 based predictive modeling from benefit of platinum-based chemotherapy.

Expression of ATM , CHK 2 and BRCA 1 predicts the clinical outcome of non-small cell lung cancer in patients receiving platinum-based chemotherapy